A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Nademanee, A
Molina, A
Forman, SJ
Kogut, N
Yamauchi, D
An, L
White, CA
Raubitschek, A
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Kaiser Permanente City Hope, Bone Marrow Transplant Program, Duarte, CA 91010 USA
[3] Idec Pharmaceut Corp, San Diego, CA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
679
引用
收藏
页码：182A / 182A
页数：1
相关论文
共 50 条
  • [11] High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma
    Provencio, Mariano
    Fayad, Luis E.
    MEDICINA CLINICA, 2008, 130 (02): : 60 - 65
  • [12] Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
    Nieto, Yago
    Thall, Peter F.
    Ma, Junsheng
    Valdez, Benigno C.
    Ahmed, Sairah
    Anderlini, Paolo
    Popat, Uday
    Jones, Roy B.
    Shpall, Elizabeth J.
    Hosing, Chitra
    Qazilbash, Muzaffar
    Kebriaei, Partow
    Alousi, Amin
    Timmons, Melissa
    Gulbis, Alison
    Myers, Alan
    Oki, Yasuhiro
    Fanale, Michelle
    Dabaja, Bouthaina
    Pinnix, Chelsea
    Milgrom, Sarah
    Champlin, Richard
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (08) : 1602 - 1609
  • [13] High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era
    Ban-Hoefen, Makiko
    Friedberg, Jonathan W.
    Kelly, Jennifer L.
    Bernstein, Steven H.
    Liesveld, Jane L.
    Young, Faith
    Fisher, Richard I.
    Constine, Louis
    Becker, Michael
    Phillips, Gordon L., II
    BLOOD, 2010, 116 (21) : 992 - 992
  • [14] High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kansu, E
    BLOOD, 2004, 104 (11) : 393B - 393B
  • [15] High-dose radioimmunotherapy/chemotherapy and autologous stem cell transplantation (ASCT) for poor risk and relapsed CD20+non-Hodgkin's lymphoma (NHL): Early feasibility report.
    Raubitschek, A
    Nademanee, A
    Molina, A
    Rodriguez, R
    White, C
    Forman, S
    BLOOD, 2000, 96 (11) : 374B - 375B
  • [16] High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result
    Michot, Jean-Marie
    Annereau, Maxime
    Danu, Alina
    Legoupil, Clemence
    Bertin, Louis
    Chahine, Claude
    Achab, Nadia
    Antosikova, Anna
    Cerutti, Ariane
    Rossignol, Julien
    Ghez, David
    Willekens, Christophe
    Dartigues, Peggy
    Lazarovici, Julien
    Lemare, Francois
    Ribrag, Vincent
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 281 - 290
  • [17] Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
    Nieto, Yago
    Valdez, Benigno C.
    Thall, Peter F.
    Wei, Wei
    Jones, Roy
    Hosing, Chitra M.
    Ahmed, Sairah
    Popat, Uday R.
    Shpall, Elizabeth J.
    Qazilbash, Muzaffar
    Gulbis, Alison M.
    Anderlini, Paolo
    Shah, Nina
    Bashir, Qaiser
    Alousi, Amin M.
    Oki, Yasuhiro
    Hagemeister, Fredrick B.
    Champlin, Richard E.
    Andersson, Borje S.
    BLOOD, 2015, 126 (23)
  • [18] Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma
    Shafey, Mona
    Duan, Qiuli
    Russell, James
    Duggan, Peter
    Balogh, Alex
    Stewart, Douglas A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (04) : 596 - 602
  • [19] High-dose Chemotherapy (HDC) with rituximab and autologous stem cell support in patients with poor prognosis non-Hodgkin's lymphoma (NHL)
    Ptushkin, V
    Mheidze, D
    Larionova, V
    Zukov, N
    Andreeva, L
    Osmanov, E
    Chimishkyan, K
    BONE MARROW TRANSPLANTATION, 2002, 29 : S95 - S95
  • [20] GEMCITABINE, BUSULFAN AND MELPHALAN (Gem/Bu/Mel) IS A NEW HIGH-DOSE CHEMOTHERAPY (HDC) REGIMEN WITH HIGH ACTIVITY IN REFRACTORY OR POOR-RISK RELAPSED NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT)
    Nieto, Y.
    Jones, R. B.
    Popat, U.
    Andersson, B.
    Valdez, B.
    Thall, P.
    Shpall, E. J.
    Chancoco, C.
    Alousi, A.
    Anderlini, P.
    Hosing, C.
    Qazilbash, M.
    Bashir, Q.
    Kebriaei, P.
    Khoui, I
    Ciurea, S.
    Parmar, S.
    Rondon, G.
    Champlin, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S206 - S206
12345